Eckert & Ziegler : is Manufacturing Partner for Bayer's Innovative Targeted Thorium Conjugates in Europe
June 19, 2018 at 08:30 am EDT
Share
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Contract
Eckert & Ziegler is Manufacturing Partner for Bayer's Innovative Targeted Thorium Conjugates in Europe
19.06.2018 / 14:29
The issuer is solely responsible for the content of this announcement.
Berlin, 19 June 2018. Eckert & Ziegler AG, a specialist for scientific, medical, and industrial applications of radioisotopes, has been selected as manufacturing partner for clinical supply of Bayer's innovative Targeted Thorium Conjugates (TTCs) in Europe. TTCs are a versatile, next-generation targeted alpha therapy (TAT). The approach uses tumor targeting molecules such as antibodies that carry alpha-particle emitting Thorium-227 to the tumor. TTCs have the potential to be used in a broad range of tumors, and also for patients who are refractory to chemotherapy or conventional targeted oncologics. Bayer has established scalable Good Manufacturing Practices (GMP) processes for the alpha-emitter Thorium-227. Eckert & Ziegler will provide the infrastructure for handling, manufacture and distribution of the TTCs for the purpose of clinical trial testing in Europe.
?"We are delighted to have been selected as a partner for this interesting and important product platform," says Dr. André Heß, Member of the Executive Board of Eckert & Ziegler and Head of the Radiopharma Segment. "The decision demonstrates how well our Radiopharma Segment can support the requirements of innovative partners by the provision of exceptional radiopharmaceutical expertise, all of which is backed-up by a world-wide logistics infrastructure. We are excited about the potential of this innovative platform technology as Thorium-227 can be coupled with various biomolecules addressing different tumor types."
About Eckert & Ziegler
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) is one of the world's largest providers of isotope technology for radiation therapy and nuclear medicine and has around 800 employees worldwide. It globally provides nuclear medicine institutions with synthesis technology, quality control instruments, and pharmaceutical grade radioisotopes, among them Yttriga(R), a precursor for Yttrium based oncology products, and GalliaPharm(R); a Gallium-68 radionuclide generator for diagnostic applications. Contributing to saving lives.
19.06.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language:
English
Company:
Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone:
49 30 941084-138
Fax:
49 30 941084-112
E-mail:
karolin.riehle@ezag.de
Internet:
www.ezag.de
ISIN:
DE0005659700
WKN:
565970
Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
Eckert & Ziegler SE is a Germany-based Company, which is a provider of isotope technology for medical, scientific and industrial use with focus on cancer therapy, industrial radiometry and nuclear-medical imaging. The Company operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
ECKERT & ZIEGLER SE 
